Stanford researchers report that a single ibogaine-based treatment cut PTSD and depression symptoms in special operations veterans by more than 80 percent at one month, with benefits seen at one year.
Story Snapshot
- Thirty male special operations veterans saw large PTSD, depression, and anxiety drops after ibogaine-based care.
- Participants improved in overall functioning immediately and at one month, with large effect sizes.
- Stanford reports the relief appeared to last one year in a follow-up study.
- The study was observational, with treatment delivered at a clinic in Mexico.
What the Stanford-led study found
Stanford-affiliated researchers studied thirty male special operations veterans with mostly mild traumatic brain injury who sought treatment with magnesium and ibogaine at a clinic in Mexico. The prospective observational study measured mental health and functioning before and after care. Researchers reported major symptom drops at one month. Post-traumatic stress disorder, depression, and anxiety scores fell sharply, alongside gains in daily functioning. Stanford’s coverage summarized reductions of about 88 percent in post-traumatic stress, 87 percent in depression, and 81 percent in anxiety.
The paper described the intervention as part of a defined protocol called Magnesium-Ibogaine: the Stanford Traumatic Injury to the Central Nervous System protocol, often shortened to MISTIC. Participants self-referred and paid for care outside the United States. The research team collected standardized measures before treatment, shortly after, and at one month. Statistical tests showed significant change, with very large effect sizes on core psychiatric symptoms at the one-month mark. The findings were published in Nature Medicine and indexed by PubMed.
Durability of benefit and what we still do not know
Stanford reported new follow-up showing that many veterans continued to report relief one year after the single ibogaine-based session. The update described recovery as rapid and surprisingly sustained for a psychiatric treatment. That longer view matters because the original paper centered on early results. While the signal looks strong, the original design was open-label and observational, not randomized or blinded. That means it cannot prove ibogaine caused the full effect, or separate the roles of magnesium or supportive care.
The cohort’s narrow profile also limits how far the results reach. All participants were men and almost all were special operations veterans with blast exposure or other brain injury. It is unclear whether women, non–special operations veterans, or civilians with post-traumatic stress disorder would respond the same way. The small sample also cannot show how common rare side effects may be. These are common gaps in early studies, and they set up the next step: larger, controlled trials that test safety and benefit with stronger methods.
Why this matters for veterans and for policy
Many veterans feel failed by the system. They see long waits, limited choices, and treatments that often help only a little. This study points to a potential path that eased severe symptoms fast for a group with heavy combat trauma. But access in the United States is blocked because ibogaine is a Schedule I substance. That status makes research and clinical use hard, pushing care across the border. When a therapy that may help is only available abroad, both left and right see a system that serves rules before people.
One year after taking ibogaine, veterans find continued relief from PTSDhttps://t.co/UElX9DCxRH
— CDUHR (@CDUHR_NYC) October 7, 2026
Policymakers have options that respect safety and science. A next step could be a federally backed, randomized trial that compares magnesium–ibogaine to a matched control, with careful heart and brain monitoring. The protocol should track depression, post-traumatic stress disorder, anxiety, sleep, cognition, and daily function over a year or more. Clear rules, data sharing, and independent sites would build trust. If results hold, leaders could weigh a regulated path that protects patients while ending medical tourism for desperate veterans.
Sources:
military.com, med.stanford.edu, nature.com, pubmed.ncbi.nlm.nih.gov
